ArticleJournal of the American Association of Nurse Practitioners2025
Countering counterfeits: The role of nurse practitioners in the fight against substandard and falsified medicines.
Article in Journal of the American Association of Nurse Practitioners, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substandard and falsified (SF) medicines, also referred to as counterfeit drugs, represent a global public health emergency. These products range from drugs with no or little active ingredient to medicines laced with illicit fentanyl. Counterfeits can be copies of brand, generic, or over-the-counter medicines. In some cases, sophisticated counterfeiters will add some of the active ingredient, making the fake medicines harder to detect. Substandard and falsified medicines affect treatment outcomes, exacerbate health inequities, and undermine health care systems around the world, including in the United States. Although significant strides have been made to enhance oversight and bolster regulatory frameworks, recent evidence underscores a glaring omission: insufficient education and training of US health care providers, including nurse practitioners, on the detection, management, and prevention of the harms related to SF medicines. Keywords: substandard and falsified medicines; counterfeit drugs, nurse practitioner education; pharmaceutical safety; online pharmacies; patient counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.